Inherited thrombophilic abnormalities and risk of portal vein thrombosis

Francesco Dentali; Matteo Galli; Monica Gianni; Walter Ageno

doi:10.1160/TH07-08-0526

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(04): 675-682
DOI: 10.1160/TH07-08-0526

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Inherited thrombophilic abnormalities and risk of portal vein thrombosis

A meta-analysis

Authors

Francesco Dentali

¹Department of Clinical Medicine, University of Insubria, Varese, Italy
Matteo Galli

¹Department of Clinical Medicine, University of Insubria, Varese, Italy
Monica Gianni

¹Department of Clinical Medicine, University of Insubria, Varese, Italy
Walter Ageno

¹Department of Clinical Medicine, University of Insubria, Varese, Italy

Abstract

Summary

Inherited thrombophilic abnormalities may have a role in the development of portal vein thrombosis (PVT).However, the prevalence of these factors in patients with PVT has been evaluated only in small studies with non-conclusive results. It was the purpose of this study to assess the risk of PVT associated with factorV Leiden (FVL) and G20210A prothrombin mutation (PTM). The MEDLINE, EMBASE, Cochrane Library databases, reference lists of retrieved articles and contact with content experts were used. Studies carried out in Western Europe comparing the prevalence of prothrombotic abnormalities in patients with PVT and in controls without a history of thromboembolic disease were included. Two reviewers independently selected studies and extracted study characteristics, quality and outcomes. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each trial and pooled using a fixed and random-effects model. Statistical heterogeneity was evaluated using the I² statistic. Sensitivity analyses were performed examining separately studies according to the etiology of PVT and to control population. Twelve studies involving more than 3,000 patients were included. The pooled OR for PVT was 1.90 (95%CI: 1.25, 2.90) in patients with FVL and 4.48 (95%CI: 3.10, 6.48) in patients with PTM. In conclusion, PVT is associated with the presence of FVL and PTM in Western Europe.

Keywords

Thrombophilia - venous thrombosis - hepatology

Full Text

References

References
1 Balfour GW, Stewart TG. Cases of enlarged spleen complicated with ascites, both depending upon varicose dilatation and thrombosis of the portal vein. Edimburrg Med J 1869; 14: 589-598.
2 Okuda K, Ohnishi K, Kimura K. et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89: 279-286.
3 Sarfeh IJ. Portal vein thrombosis associated with cirrhosis: clinical importance. Arch Surg 1979; 114: 902-905.
4 Gayowski TJ, Marino IR, Doyle HR. et al. A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. J Surg Res 1996; 60: 333-338.
5 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231.
6 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-1173.
7 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
8 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
9 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
10 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-1134.
11 Rosendaal FR, Doggen CJ, Zivelin A. et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
12 Salomon O, Steinberg DM, Zivelin A. et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-518.
13 Emmerich J, Rosendaal FR, Cattaneo M. et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism– pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-816.
14 Ho WK, Hankey GJ, Quinlan DJ. et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
15 McGinn T, Wyer PC, Newman TB. et al for Evidence-Based Medicine Teaching Tips Working Group. Tips for learners of evidence-based medicine: 3. Measures of observer variability (kappa statistic). CMAJ 2004; 171: 1369-1373.
16 Stroup DF, Berlin JA, Morton SC. et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. J Am Med Assoc 2000; 283: 2008-2012.
17 Hayden GF, Kramer MS, Horwitz RI. The casecontrol study. A practical review for the clinician. J Am Med Assoc 1982; 247: 326-331.
18 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
19 Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
20 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
21 Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. Br Med J 2001; 323: 101-105.
22 Mahmoud AEA, Elias E, Beauchamp N. et al. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798-800.
23 Chamouard P, Pencreach E, Maloisel F. et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999; 116: 144-148.
24 Amitrano L, Brancaccio V, Guardascione MA. et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-348.
25 Egesel T, Buyukasik Y, Dundar SV. et al. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol 2000; 30: 66-71.
26 Denninger MH, Chait Y, Casadevall N. et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31: 587-591.
27 Gomez MR, Garcia ES, Lacomba DL. et al. Antiphospholipid antibodies are related to portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2000; 31: 237-240.
28 Janssen HLA, Meinardi JR, Vleggaar FP. et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: Results of a case-control study. Blood 2000; 96: 2364-2368.
29 Amitrano L, Brancaccio V, Guardascione MA. et al. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol 2001; 96: 146-149.
30 Madonna P, De Stefano V, Coppola A. et al. G20210A prothrombin gene mutation and other trombophilic polymorphisms in patients with portal or hepatic venous thrombosis. Gastroenterology 2001; 120: 1059-1060.
31 Janssen HLA. Role of coagulation in the natural history and treatment of portal vein thrombosis. J Gastroenterol Hepatol 2001; 16: 595-596.
32 De Stefano V, Teofili L, Leone G. et al. Acquired and inherited risk factors for splanchnic venous thrombosis. Blood 2001; 97: 3314-3315.
33 Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002; 70: 126-132.
34 Amitrano L, Brancaccio V, Guardascione MA. et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: Role of genetic thrombophilia. Endoscopy 2002; 34: 535-538.
35 Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002; 71: 89-93.
36 Elefsiniotis IS, Diamantis ID, Dourakis SP. et al. Anticardiolipin antibodies in chronic hepatitis B and chronic hepatitis D infection, and hepatitis B-related hepatocellular carcinoma. Relationship with portal vein thrombosis. Eur J Gastroenterol Hepatol 2003; 15: 721-726.
37 Oksuzoglu G, Bayraktar Y, Arslan S. et al. Portal vein thrombosis in cirrhotics: Related with anticardiolipin antibodies?. Hepato-Gastroenterology 2003; 50: 1527-1530.
38 Barcellona D, Fenu L, Cauli C. et al. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. Thromb Haemost 2003; 90: 1061-1064.
39 Amitrano L, Guardascione MA, Brancaccio V. et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-741.
40 Samonakis DN, Koutroubakis IE, Sfiridaki A. et al. Hypercoagulable states in patients with hepatocellular carcinoma. Dig Dis Sci 2004; 49: 854-858.
41 Erkan O, Bozdayi AM, Disibeyaz S. et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-343.
42 Primignani M, Martinelli I, Bucciarelli P. et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41: 603-608.
43 Fernandez-Miranda C, Coto A, Martinez J. et al. Effect of hyperhomocysteinemia and methylenetetrahydrofolate reductase 677CT mutation in venous thromboembolism risk of young adults. Medicina Clinica 2005; 124: 532-534.
44 Mangia A, Villani MR, Cappucci G. et al. Causes of portal venous thrombosis in cirrhotic patients: The role of genetic and acquired factors. Eur J Gastroenterol Hepatol 2005; 17: 745-751.
45 Matsutani S, Maruyama H, Akiike T. et al. Study of portal vein thrombosis in patients with idiopathic portal hypertension in Japan. Liver International 2005; 25: 978-983.
46 Maakaroun A, Delahousse B, Fimbel B. et al. G20210A prothrombin gene mutation appears as the most important inherited prothrombotic risk factor in ‘idiopathic’ portal vein thrombosis. ISTH Congress abstract. J Thromb Haemost 2003; 1 Abstract P0335.
47 Macarone Palmieri N, Tufano A, Coppola A. et al. Genetic and acquired risk factors in patients with portal and mesenteric venous thrombosis. ISTH Congress abstract. J Thromb Haemost 2005; 3 Abstract P2326.
48 Amitrano L, Guardascione MA, Ames PR. et al A. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thromb Haemost 2006; 95: 221-223.
49 Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol 2000; 32: 865-871.
50 Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med 1979; 48: 627-639.
51 Robson SC, Kahn D, Kruskal J. et al. Disordered hemostasis in extrahepatic portal hypertension. Hepatology 1993; 18: 853-857.

Supplementary Material

Online Supplementary Material (PDF) (PDF) (opens in new window)